Investigational drug · Phase 2
LY3537021
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "LY3537021"
First trial start
2025
Nov 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY3537021", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nausea
- Vomiting
- Drug-Related Side Effects and Adverse Reactions
- Neoplasms
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "LY3537021" as an intervention, largest first.
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07169851 · 204 participants (planned) · Start Nov 28, 2025 · Primary completion Dec 2026
Drug: LY3537021; Placebo and 2 more · For: Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions and 1 more
Sites: Greenbrae, California; Irvine, California; Los Alamitos, California · 67 sites in all
- A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes MellitusCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04586907 · 85 participants · Start Nov 23, 2020 · Primary completion Nov 30, 2021
Drug: LY3537021; Placebo · For: Healthy; Type 2 Diabetes Mellitus
Sites: Singapore, Singapore
Eli Lilly and CompanyEli Lilly (LLY)
NCT05444569 · 47 participants · Start Aug 8, 2022 · Primary completion Feb 24, 2023
Drug: LY3537021; Liraglutide and 1 more · For: Healthy
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
- Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.
Roell W, Alsina-Fernandez J, Qu H, et al. · Mol Metab 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.